Psoralen-Induced Cholestasis via ERK1/2

The 2024 study by Chen, Qian, Li, He, and Li examined how psoralen and isopsoralen, two major bioactive constituents of Psoraleae Fructus, contribute to estrogen-induced cholestasis. Published in Chemical Research in Toxicology, the work is important because it moves beyond the observation that these compounds can injure the liver and investigates a specific signaling mechanism: activation of extracellular signal-regulated kinases 1 and 2, or ERK1/2. The reference study links estrogen-like activity, impaired bile acid handling, and increased ERK1/2 phosphorylation in a single experimental framework.

Study Background and Research Question

Cholestasis is characterized by impaired bile formation or flow and can arise when hepatocytes cannot synthesize, transport, or excrete bile acids normally. Estrogen-induced cholestasis is clinically relevant because abnormal estrogen exposure has been associated with disrupted bile acid homeostasis, with a higher reported susceptibility in women. Estrogen signaling can involve nuclear estrogen receptors, including ERα and ERβ, as well as downstream kinase pathways that alter transcription and cell physiology.

Psoraleae Fructus, derived from the dried fruits of Psoralea corylifolia, has recognized estrogen-like activity. Psoralen and isopsoralen are among its principal constituents, but their relationship to estrogen-induced cholestasis had not been fully defined. Earlier observations implicated these compounds in liver injury and changes in bile acid transport, yet the initiating estrogen-like response and the downstream role of ERK1/2 remained unresolved.

The central research question was therefore whether psoralen and isopsoralen induce cholestatic liver injury through estrogen-like activity and, if so, whether ERK1/2 activation is a critical part of that process.

Key Innovation from the Reference Study

The study’s main innovation is its mechanistic integration of three levels of evidence. First, it assessed estrogenic responses by measuring estrogen-related molecular and biochemical markers. Second, it evaluated cholestatic injury through liver morphology and bile flow. Third, it tested whether ERK1/2 inhibition could rescue the phenotype. This design distinguishes a general toxic effect from a pathway-linked mechanism.

The authors found that psoralen and isopsoralen increased esr1, cyp19a1b, estradiol, and vitellogenin signals in zebrafish larvae. Exemestane, an aromatase antagonist, blocked these estrogen-like effects, supporting the interpretation that the compounds act through an estrogen-associated mechanism. The same exposures also increased liver fluorescence areas and inhibited bile flow, providing functional evidence of cholestatic injury rather than relying only on gene-expression changes.

Most importantly, the work connected this estrogen-like response to elevated ERK1/2 phosphorylation. The ERK1/2 inhibitor GDC-0994 and exemestane both produced significant rescue effects, although they interrogate different points in the proposed pathway. This pharmacologic convergence supports ERK1/2 as a downstream mediator and identifies ERK phosphorylation inhibition as a useful experimental approach for dissecting phytoestrogen-associated cholestasis.

Methods and Experimental Design Insights

Zebrafish larvae were used as the primary model. Larval zebrafish are particularly useful for early toxicology because hepatic morphology, bile flow, and fluorescent functional readouts can be assessed in an intact organism. In this study, the model allowed the researchers to compare estrogen-like activity with hepatobiliary dysfunction in the same biological system.

The experimental logic proceeded in stages. Psoralen and isopsoralen were applied to determine whether they could activate estrogen-responsive endpoints. The authors then measured liver fluorescence and bile flow to characterize cholestatic injury. Gene-expression analysis focused on several functional groups:

• Bile acid synthesis: cyp7a1 and cyp8b1.
• Bile acid transport: abcb11b and slc10a1.
• Bile acid sensing and feedback: nr1h4 and nr0b2a.
• Estrogen-related responses: esr1, cyp19a1b, estradiol, and vitellogenin.

At the reported 80 μM exposure condition, psoralen and isopsoralen increased estrogen-associated endpoints, as described in the published study. The authors also monitored liver fluorescence area and bile flow inhibition, then examined whether pathway-directed interventions could reverse the phenotype. This combination of molecular, functional, and rescue endpoints is stronger than measuring a single toxicity marker.

Protocol Parameters

• Model system: Use larval zebrafish when the objective is to connect compound exposure with hepatobiliary morphology, bile flow, and transcriptional responses in vivo.
• Estrogenic activity assessment: The reference study evaluated psoralen and isopsoralen at 80 μM and measured esr1, cyp19a1b, estradiol, and vitellogenin. These values are literature-backed conditions rather than universal exposure recommendations.
• Cholestasis readouts: Combine liver fluorescence area, bile flow inhibition, and bile acid pathway gene expression to avoid interpreting a single endpoint in isolation.
• Mechanistic rescue: Include an estrogen-pathway comparator such as exemestane and an ERK1/2 inhibitor in parallel arms. Use concentrations and exposure timing established by the relevant primary study or laboratory validation rather than extrapolating from unrelated models.
• Pathway confirmation: Measure ERK1/2 phosphorylation alongside functional rescue. A reduction in phospho-ERK1/2 with improved bile flow would provide more direct evidence of pathway engagement than transcriptional changes alone.

Core Findings and Why They Matter

Psoralen and isopsoralen produced a coordinated phenotype consistent with estrogen-associated cholestasis. They increased estrogen-responsive markers, caused visible hepatic abnormalities, and inhibited bile flow. At the same time, they reduced the expression of genes involved in bile acid synthesis, transport, and receptor-mediated feedback. Reduced abcb11b and slc10a1 expression is particularly relevant because impaired transporter activity can limit bile acid export and uptake, promoting intracellular accumulation and hepatobiliary stress.

The findings also refine the interpretation of bile acid gene changes. A decrease in selected synthesis genes does not necessarily indicate protection; it may reflect a disrupted regulatory state in which bile acid production, transport, and feedback control are no longer coordinated. The simultaneous reduction of nr1h4 and nr0b2a, together with transporter changes, suggests broader impairment of bile acid homeostasis.

Increased ERK1/2 phosphorylation provides a signaling link between estrogen-like exposure and cholestatic injury. Rescue by GDC-0994 strengthens the case that ERK1/2 is functionally involved, while rescue by exemestane places estrogenic signaling upstream or parallel to the injury phenotype. The results do not prove that ERK1/2 is the only mediator, but they establish a testable model in which estrogen-like compounds activate ERK1/2 and alter hepatobiliary gene regulation.

Comparison with Existing Internal Articles

The internal article ERK1/2 Activation Mediates Cholestatic Injury by Psoralen Compounds presents the same study as a concise mechanistic bridge between phytoestrogens and liver injury. Its emphasis is useful for quickly identifying the proposed causal chain, whereas the reference paper provides the experimental detail and endpoint structure needed to evaluate that interpretation.

By contrast, GDC-0994: Precision ERK1/2 Inhibitor for Liver and Cancer Models is more workflow-oriented and extends the discussion toward pathway inhibition in different research settings. It can help frame assay planning, but it should not be treated as additional evidence for the specific psoralen findings. The primary study remains the appropriate source for the zebrafish phenotype, gene-expression results, and rescue interpretation.

Limitations and Transferability

The principal limitation is model scope. Larval zebrafish provide valuable whole-organism evidence, but their developmental stage, metabolism, transporter biology, and exposure conditions do not fully reproduce adult human cholestasis. The reported exposure concentration also should not be interpreted as a clinically relevant human dose without pharmacokinetic and toxicological analysis.

Pharmacologic rescue is informative but not definitive proof of pathway exclusivity. ERK1/2 inhibitors may affect signaling beyond the intended node, and improved morphology after inhibition does not establish whether ERK1/2 activation is an initiating event, an amplifying response, or one component of a parallel injury network. Follow-up studies in mammalian hepatocytes, organoids, and animal models would be useful for confirming target engagement, exposure relationships, transporter function, and relevance to human estrogen-induced cholestasis.

Why this cross-domain matters, maturity, and limitations

ERK1/2 is also a central node in the RAS/RAF/MEK/ERK signaling cascade and the broader MAP kinase pathway studied in cancer biology. This creates a scientifically reasonable bridge between cholestatic liver injury and oncology models: the same signaling machinery can regulate cell survival, differentiation, and proliferation in different tissues. However, the reference study does not establish tumor cell proliferation suppression, anticancer efficacy, or equivalence between zebrafish cholestasis and tumor biology. The cross-domain connection is therefore hypothesis-generating and mechanistic, not evidence that a liver-injury result directly predicts clinical cancer benefit.

Research Support Resources

For experiments designed to reproduce or extend the ERK1/2 rescue arm of the reference study, researchers can use GDC-0994 (SKU B5817), a selective ERK1/2 inhibitor, in accordance with the product documentation and laboratory-specific validation. It may support comparative studies of phospho-ERK1/2, bile flow, hepatic fluorescence, and bile acid pathway genes. Concentration, solvent handling, exposure duration, and controls should be optimized for the selected zebrafish, cellular, or organoid model rather than transferred unchanged across systems.